



27123

PATENT TRADEMARK OFFICE

Docket No. 3856-4006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Reissue of:**

**U.S. Patent No. 5,556,838**

David J. **MAYER** et al.

Filed: May 19, 1994

Granted: September 17, 1996

Serial No.: TBA

For: Inhibiting the Development of Tolerance to and/or  
Dependence on an Addictive Substance

Commissioner for Patents  
U.S. Patent & Trademark Office  
Washington, D.C. 20231

**SIR:**

**REISSUE DECLARATION AND  
POWER OF ATTORNEY BY ASSIGNEE**

**I hereby declare that:**

- I.** My residence, post office address and citizenship are stated below next to my name.
- II.** I am authorized to act in connection with the aforesaid patent on behalf of the assignee  
Virginia Commonwealth University.
- III.** The entire right, title and interest in the above identified patent is vested in the assignee  
Virginia Commonwealth University, as certified on the attached Certification under 37  
C.F.R. § 3.73(b).

- IV. I believe David J. MAYER, Donald D. PRICE, Jianren MAO, and John W. LYLE to be the original and joint inventors of the subject matter which is described and claimed in U.S. Patent No. 5,556,838 (“the ‘838 patent”) granted on September 17, 1996, and for which a reissue patent is sought on the invention entitled, **“INHIBITING THE DEVELOPMENT OF TOLERANCE TO AND/OR DEPENDENCE ON AN ADDICTIVE SUBSTANCE.”**
- V. I have reviewed and understand the contents of the ‘838 patent, including the claims as amended in any amendment and specifically referred to in this oath or declaration.
- VI. I acknowledge the duty to disclose information known to me which is material to patentability as defined in 37 C.F.R. §§ 1.56 and 1.175(a)(7). In compliance with this duty, filed herewith is an Information Disclosure Statement and copies of the references cited therein in accordance with 37 C.F.R. § 1.98.
- VII. I hereby offer to surrender U.S. Letters Patent No. 5,556,838 pursuant to 37 C.F.R. § 1.178.
- VIII. All errors corrected by this reissue application up to the time of filing the oath or declaration under 37 C.F.R. § 1.175 occurred without any deceptive intent on the part of the applicants.

**IX.** Pursuant to 37 C.F.R. § 1.175(a)(1), I verily believe that the '838 patent is wholly or partly inoperative or invalid by reason of applicants claiming more than they were entitled to claim because of errors which arose without deceptive intention on the part of the applicants.

One error being relied upon as a basis for reissue is applicants claiming more than they were entitled to by including within the scope of claim 1 certain "non-synthetic" NMDA receptor antagonists as a result of a prosecution error by applicants. Applicants limited their claims to "synthetic" non-toxic NMDA receptor antagonists in a preliminary amendment filed on May 19, 1994, to obviate a potential rejection based on U.S. Patent No. 5,183,807 (The Delle Valle patent) during the prosecution of the '838 patent application. However, the claims that contained the "synthetic" limitation were later cancelled and replaced, and applicants inadvertently failed to include the "synthetic" limitation in the claims that issued in the '838 patent.

Another error being relied upon as a basis for reissue includes claiming more than the applicants were entitled to claim by including within the scope of claim 1 of the '838 patent, the combination of morphine and ketamine which is disclosed in Bristow et al., "Subcutaneous ketamine analgesia: postoperative analgesia using subcutaneous infusions of ketamine and morphine," Annals of the Royal College of Surgeons of England, Vol. 71 (1989).

A further reason for amending the claims issued in the '838 patent is the disclosure in the published article by Chapman and Dickenson, entitled "The

Combination of NMDA antagonism and morphine produces profound antinociception in the rat dorsal horn”, *Brain Research*, 573 (1992) 321-323. This article discloses a composition containing morphine and 7CK, the latter being described as a “selective antagonist at the glycine site on the NMDA receptor.” The compound 7CK is not described as being “nontoxic.” The Chapman et al article also suggests that morphine could be combined with either ketamine or AP5 and AP5 is not described as being “nontoxic.” To avoid any issue as to whether the nontoxic substance in the claims of the ‘838 patent embraces 7CK or AP5, the claims presented in this reissue claims not only exclude ketamine, but also exclude 7CK and AP5 from the nontoxic substance.

Amended independent claim 1 (with added language noted with underlines) and independent reissue claims 3, 4 and 5 correct these errors as follows:

1. *A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that blocks the N-methyl-D-aspartate receptor or a major intracellular consequence of N-methyl-D-aspartate receptor activation, and which excludes ketamine, AP-5 and 7-chlorokynurenate, the addictive substance being selected from the group consisting of alfentanil, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.*

3. *A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that blocks the N-methyl-D-aspartate receptor and consists essentially of a morphinan or blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation, the addictive substance being selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.*
4. *A formulated pharmaceutical composition comprising an addictive substance and a non-toxic synthetic substance, the addictive substance being selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, levorphanol, methadone, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof, the non-toxic synthetic substance being selected from the group consisting of dextromethorphan, dextrorphan, and pharmaceutically acceptable salts thereof.*
5. *A formulated pharmaceutical composition comprising an addictive substance and a non-toxic synthetic substance, the addictive substance being selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, levorphanol, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof, the non-toxic synthetic substance being a blocker of the N-methyl-D-aspartate receptor and consisting essentially of morphinans.*

Another error relied upon for this reissue is that it was error for applicants not to provide claims of more intermediate and more narrow scope than the claims that issued in the '838 patent. Accordingly, the following additional dependent claims 6-16 are being added. Newly added claims 15 and 16, include the subject matter of claim 2.

6. *A composition according to claims 1, 3, 4 or 5 wherein the addictive substance is selected from the group consisting of alfentanil, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, methadone, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof.*
7. *A composition according to claims 1, 3, 4 or 5 wherein the addictive substance is selected from the group consisting of alfentanil, codeine, dihydrocodeine, fentanyl, isomethadone, methadone, pethidine, and pharmaceutically acceptable salts thereof.*
8. *A composition according to claims 1, 3, 4 or 5 wherein the addictive substance is selected from the group consisting of codeine, methadone, and pharmaceutically acceptable salts thereof.*
9. *A composition according to claims 1, 3, 4 or 5 wherein the addictive substance includes morphine or a pharmaceutically acceptable salt thereof.*
10. *A composition according to claims 1, 3, 4 or 5 wherein the addictive substance includes oxycodone or a pharmaceutically acceptable salt thereof.*
11. *A composition according to claims 1, 3, 4 or 5 wherein the addictive substance includes hydrocodone or a pharmaceutically acceptable salt thereof.*
12. *A composition according to claims 1, 3, 4 or 5 wherein the addictive substance includes oxymorphone or a pharmaceutically acceptable salt thereof.*

13. *A composition according to claims 1, 3, 4 or 5 wherein the addictive substance includes hydromorphone or a pharmaceutically acceptable salt thereof.*
14. *A composition according to claims 1, 3, 4 or 5, in oral dosage form.*
15. *A composition according to claims 3, 4 or 5, in sustained release dosage form.*
16. *A composition according to claims 1, 3, 4 or 5, in oral dosage and sustained release dosage form.*

X. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

XI. I hereby specify the following as the correspondence address to which all communications about this application are to be directed:

**SEND CORRESPONDENCE TO:**

Arnold I. Rady  
MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, NY 10154-0053

**DIRECT TELEPHONE CALLS TO:**

Arnold I. Rady (212-758-4800)

**XII.** I hereby appoint the following attorneys and/or agents with full power of substitution and revocation, to prosecute this application, to receive the patent, and to transact all business in the Patent and Trademark Office connected therewith:


John C. Vassil (Reg. No. 19,098), Alfred P. Ewert (Reg. No. 19,887), David H. Pfeffer (Reg. No. 19,825), Harry C. Marcus (Reg. No. 22,390), Robert E. Paulson (Reg. No. 21,046), Stephen R. Smith (Reg. No. 22,615), Kurt E. Richter (Reg. No. 24,052), J. Robert Dailey (Reg. No. 27,434), Eugene Moroz (Reg. No. 25,237), John F. Sweeney (Reg. No. 27,471), Arnold I. Rady (Reg. No. 26,601), Christopher A. Hughes (Reg. No. 26,914), William S. Feiler (Reg. No. 26,728), Joseph A. Calvaruso (Reg. No. 28,287), James W. Gould (Reg. No. 28,859), Richard C. Komson (Reg. No. 27,913), Israel Blum (Reg. No. 26,710), Bartholomew Verdirame (Reg. No. 28,483), Maria C.H. Lin (reg. No. 29,323), Joseph A. DeGirolamo (Reg. No. 28,595), Michael P. Dougherty (Reg. No. 32,730), Seth J. Atlas (Reg. No. 32,454), Andrew M. Riddles (Reg. No. 31,657), Bruce D. DeRenzi (Reg. No. 33,676), Mark J. Abate (Reg. No. 32,527), John T. Gallagher (Reg. No. 35,516), Steven F. Meyer (Reg. No. 35,613), Kenneth H. Sonnenfeld (Reg. No. 33,285), Tony V. Pezzano (Reg. No. 38,271), Andrea L. Wayda (Reg. No. 43,979) and Walter G. Hanchuk Reg. No. (35,179) of Morgan & Finnegan, L.L.P. whose address is: 345 Park Avenue, New York, New York, 10154; and Michael S. Marcus (Reg. No. 31,727) and John E. Hoel (Reg. No. 26,279) of Morgan & Finnegan, L.L.P., whose address is 1775 Eye Street, Suite 400, Washington, D.C. 20006.



Reissue Declaration  
U.S. Patent No. 5,556,838

Docket No. 3856-4006

Richard C. Franson, Ph.D.  
Director, Office of Technology Transfer  
President, VCU – Intellectual Property Foundation  
Virginia Commonwealth University

Signature:  Date: 6/15/01

Citizenship of person signing: USA

Post Office Address of person signing: Office of Technology Transfer, Virginia  
Commonwealth University, 1101 E. Marshall St., Sanger Hall, Room 1-026, Richmond, VA  
23298-0568

Patentee: David J. MAYER Citizenship: USA

Residence/Post Office Address: 502 Honaker Ave., Richmond, VA 23226

Patentee: Donald D. PRICE Citizenship: USA

Residence/Post Office Address: University of Florida, Brain Institute, Gainesville, FL 32611-  
7345

Patentee: Jianren MAO Citizenship: USA

Residence/Post Office Address: Massachusetts General Hospital, Pain Center, Harvard  
Medical School, 15 Parkman Street, Suite WACC 324, Boston, MA 02114

Patentee: John W. LYLE Citizenship: USA

Residence/Post Office Address: 28 Inlet Terrace, Belmar, NJ 07719